References
- Lamm D, Stogdill V, Stogdill B, Crispen R. Complications of BCG immunotherapy in 1278 patients with bladder cancer. J Urol. 1986;135(2):272–4.
- Bernini L, Manzini CU, Giuggioli D, Sebastiani M, Ferri C. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 2013;12(12):1150–9.
- Lamm DL, van del Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147(3):596–600.
- Tinazzi E, Ficarra V, Simeoni S, Artibani W, Lunardi C. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006;26(6):481–8.
- Clavel G, Grados F, Lefauveau P, Fardellone P. Osteoarticular side effects of BCG therapy. Joint Bone Spine. 2006;73(1):24–8.
- Murata H, Adachi Y, Ebitsuka T, Chino Y, Takahashi R, Hayashi T, et al. Reiter's syndrome following intravesical bacilli bilie de Calmette-Guerin treatment for superficial bladder carcinoma: report of six cases. Mod Rheumatol. 2004;14(1):82–6.
- Yamaguchi A, Tsuchiya N, Mitsui H, Shiota H, Ogawa A, Tokunaga K, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum. 1995;38(11):1672–7.